Primer: Keymed Biosciences (2162 HK) - Aug 2026
Keymed is successfully transitioning into a commercial-stage biopharmaceutical company, anchored by the recent multi-indication approval of its...
94 Views
China Healthcare Weekly Wrap (21-25 Sep)
We highlight 1) key studies to watch for upcoming October's ESMO updates, 2) deal flows Innocare/Lilly, BoomRay/Novartis, Earendil Labs...
95 Views
China Healthcare Weekly Wrap (7-11 Sep)
1) Insilico AI drug could slow aging indicated by early data; 2) Genscript US$300m placing for AIDD capex; 3) two long-acting TSLP-targeting drugs...
88 Views
APAC Healthcare Weekly (Sept 6) – Simcere, Hutchmed, Akeso, Daiichi Sankyo, Alteogen, Pharmaessentia
Simcere and Hutchmend inked outlicensing deals with Roche and GSK, respectively. Akeso’s ivonescimab extends lives vs Keytruda. Alteogen inked...
103 Views
China Biotech/Pharma Sector: 1H26 Results Wrap and Pipeline Catalyst Table
We track 36 major commercial-stage biotech/pharma companies in China for key takeaways/readthroughs and updated sector's major pipeline catalysts...
112 Views